English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/211195
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

PTP1B deficiency protects against metabolic dysfunction in glucose homeostasisupon Olanzapine intraperitoneal treatment

AuthorsFerreira, Vítor; Grajales, Diana; Rada, Patricia; Garcia-Martinez, Irma; Valverde, Ángela M.
Issue Date24-Feb-2019
CitationMarie Curie alumni assciation annual conference (2019)
AbstractSchizophrenia is a chronic mental disorder that affects approximately 50 million people worldwide. Also, it is associated with psychotic experiences that not allow patients to have a normal life. Fortunately, treatments used can suppress the symptomatology and lead to a productive life and integration in the society. According to the current guidelines, the first line in schizophrenia’s therapy are the second generation antipsychotic drugs (SGA). Besides being D2 receptors antagonists/partial agonists, the SGAs have the ability to interact also with serotonergic, histaminergic and other receptors; minimizing the symptomatology and not resulting in neurological side effects (contrarily to first generation antipsychotic drugs). Nevertheless, recent clinical observations show a variety of metabolic dysfunctions in patients under SGAs treatment, such as abnormal gain weight, hyperglycemia and dyslipidemia. However, the molecular mechanisms behind these alterations are still very poorly understood. Having this in consideration, the objective of this work was to study the effect of Olanzapine administration in wild-type (WT) and PTP1B-deficient (KO) mice on glucose homeostasis and the mechanisms involved. Of interest, PTP1B is the main tyrosine phosphatase of the insulin receptor, and PTP1B KO mice are protected against insulin resistance and development of type 2 diabetes mellitus. After administration of 10 mg/kg/day of Olanzapine for 8 weeks to WT and PTP1B-KO mice, the glucose homeostasis tests suggest that Olanzapine induced insulin resistance only in WT mice. Also, primary hepatocytes from WT mice treated with Olanzapine showed lower glucose uptake than those from non-treated WT mice. In contrast, Olanzapine treatment of PTP1B KO mice significantly increased hepatocyte glucose uptake, suggesting that Olanzapine-induced insulin resistance is at least in part dependent on PTP1B. These results support the relevance of PTP1B in Olanzapine-induced insulin resistance in hepatocytes.
DescriptionResumen del trabajo presentado en Marie Curie alumni assciation annual conference, celebrada en Viena (Austria) del 24 al 25 de febrero de 2019.
URIhttp://hdl.handle.net/10261/211195
Appears in Collections:(IIBM) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
PTP1B_Silva_Art2019.pdf1,03 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.